GERMANTOWN, Md.–(BUSINESS WIRE)–Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in two upcoming investor conferences.
Stifel 2021 Virtual Healthcare Conference
Management will participate in a virtual fireside chat on Tuesday, November 16, 2021 at 8:40am ET.
Jefferies London Healthcare Conference
A presentation from management will be made available on Thursday, November 18, 2021 at 3:00am ET.
Interested parties may access these live and on-demand webcasts on the “Investors” section of the Company’s website at www.senseonics.com.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics’ CGM systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.
Contacts
Senseonics Investor Relations Contact:
Lynn Lewis or Philip Taylor
Investor Relations
415-937-5406
Investors@senseonics.com
Black Book Research Q4 flash survey shows health plans shifting from effort-based sourcing to KPI-backed…
CHICAGO, IL / ACCESS Newswire / December 24, 2025 / Healthcare investors have seen this…
$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon…
The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment…
TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…
Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec.…
